Journal: bioRxiv

Article Title: Colocalization of Cancer Associated Biomarkers on Single Extracellular Vesicles for Early Cancer Detection

doi: 10.1101/2023.02.07.527360

Figure Lengend Snippet: Performance of (A) Mercy Halo biomarker combination FOLR1/MUC16, (B) Mercy Halo biomarker combination BST2/FOLR1/MUC16, and (C) CA125 ELISA in a cohort of healthy controls (n=24), patients with benign ovarian masses (n=26), and patients with stage I (n=9), II (n=9), III (n=15), and IV (n=4) HGSOC. All plots are presented as 40 minus the cycle threshold (40-Ct). (D) ROC curves for distinguishing all HGSOC cases from controls (patients with no symptoms or benign ovarian masses) using Mercy Halo and CA125 ELISA. (E) ROC curves for distinguishing early-stage HGSOC cases from controls.

Article Snippet: A commercial CA125 ELISA kit (R&D SYSTEMS, Human CA125/MUC16 Quantikine ELISA kit, cat # DCA 125) was used to gauge the relative sensitivity and specificity of Mercy Halo.

Techniques: Biomarker Discovery, Enzyme-linked Immunosorbent Assay

Journal: World Journal of Gastrointestinal Oncology

Article Title: Establishment of a cholangiocarcinoma risk evaluation model based on mucin expression levels

doi: 10.4251/wjgo.v16.i4.1344

Figure Lengend Snippet: Clinical significance and heterogeneity of mucins in cholangiocarcinoma. A: Survival curves generated using cohort 2 data illustrating the relationship between cholangiocarcinoma (CCA) patient survival and the mRNA levels of mucins; B: Uniform manifold approximation and projection plot visually representing the tumor cell sub-clusters within the integrated CCA dataset; C: Violin plots depicting of the relative gene expression levels of MUC1 , MUC4 , MUC5AC , MUC5B , MUC13 , and MUC16 in CCA tumor sub-clusters.

Article Snippet: Sections were then incubated with primary antibodies against MUC13 (Abcam, Cat ab235450), MUC16 (Origene, Cat ZM-0019), CD163 (Origene, Cat ZM-0428), and CD66b (Abcam, Cat ab300122) at 4 °C overnight.

Techniques: Generated, Gene Expression

Journal: World Journal of Gastrointestinal Oncology

Article Title: Establishment of a cholangiocarcinoma risk evaluation model based on mucin expression levels

doi: 10.4251/wjgo.v16.i4.1344

Figure Lengend Snippet: Interaction with neutrophils and activated nuclear factor kappa-light-chain-enhancer of activated B cells signaling in MUC16 -high tumor cells of cholangiocarcinoma. A: Top 20 enriched signaling pathways of the differentially expressed genes of MUC16 -high cells; B: Interleukin-1 signaling pathway activity among MUC16 -high cells, MUC16 -low cells, and cells in tumor microenvironment; C and D: Feature-plots showing the expression level and distribution of IL1B and CSF3R in myeloid cell sub-clusters. Red circles showing the enrichment of IL1B and CSF3R in M16 sub-cluster; E: Gene set enrichment analysis plots showing the enrichment of genes from MUC16 -high cells (left) and MUC16 -low cells (right) in the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathway. The P value and normalized enrichment score are indicated on the plot; F: Violin plots showing relative expression levels of key regulatory genes ( RELA , NFKB1 , NFKB2 , IKBKG ) of the NF-κB pathway in MUC16 -high vs MUC16 -low cells; G: Immunohistochemistry double staining showing the adjacent distribution of MUC16-high cells ( MUC16 -positive, brown) and neutrophils (CD66b-positive, purple) in cholangiocarcinoma (CCA). Scale bar, 100 μm; H: Correlation analysis between the expression of MUC16 and CSF3R in CCA tumor samples from cohort 10; I: Correlation analysis between the expression of MUC16 and NFKB1 , NFKB2 , and RELA in CCA tumor samples from cohort 10.

Article Snippet: Sections were then incubated with primary antibodies against MUC13 (Abcam, Cat ab235450), MUC16 (Origene, Cat ZM-0019), CD163 (Origene, Cat ZM-0428), and CD66b (Abcam, Cat ab300122) at 4 °C overnight.

Techniques: Protein-Protein interactions, Activity Assay, Expressing, Immunohistochemistry, Double Staining

Journal: World Journal of Gastrointestinal Oncology

Article Title: Establishment of a cholangiocarcinoma risk evaluation model based on mucin expression levels

doi: 10.4251/wjgo.v16.i4.1344

Figure Lengend Snippet: Establishment of cholangiocarcinoma risk evaluation model based on mucin levels. A: RNA levels of MUC1 , MUC13 , MUC16 , MUC4 , MUC5AC and MUC5B in cholangiocarcinoma (CCA) samples from cohort 2; B: Survival curve based on RNA levels of mucins showing the relationship between the risk factor and survival of CCA patients from cohort 2; C-F: Gene set enrichment analysis plots showing the enrichment of differentially expressed genes in high-risk patients in cell proliferation pathway, metastasis pathway, tamoxifen resistance pathway, and cisplatin resistance pathway. The P values and normalized enrichment score are indicated on the plots; G: Survival curve based on protein expression levels of mucins showing the relationship between the risk factor and survival of CCA patients from cohort 2; H-J: Correlation analyses of vascular invasion, regional lymph node metastasis, and tumor node metastasis stage with CCA risk factor; K: Survival curve based on RNA expression levels of mucins showing the relationship between the risk factor and survival of CCA patients from cohort 10.

Article Snippet: Sections were then incubated with primary antibodies against MUC13 (Abcam, Cat ab235450), MUC16 (Origene, Cat ZM-0019), CD163 (Origene, Cat ZM-0428), and CD66b (Abcam, Cat ab300122) at 4 °C overnight.

Techniques: Expressing, RNA Expression